Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a combination therapy for the eradication of *Helicobacter pylori* infection. It typically contains a proton pump inhibitor (PPI), amoxicillin, and clarithromycin. The specific PPI and its dose may vary.
## Primary Indications
Eradication of *Helicobacter pylori* in patients with peptic ulcer disease.
## Adult Dosing
* **General Regimen:** Typically a 10- or 14-day course.
* **Proton Pump Inhibitor (e.g., Omeprazole):** 20-40 mg twice daily.
* **Amoxicillin:** 1000 mg twice daily.
* **Clarithromycin:** 500 mg twice daily.
* **Specific dosing varies by regimen and product. Refer to local protocols or product monographs for precise combinations and durations.**
## Pediatric Dosing
* Dosing for pediatric patients is not well-established for this specific combination product. Dosing of individual components should be guided by age, weight, and renal/hepatic function, and determined by a pediatrician.
## Dose Adjustments
* **Renal Impairment:** Clarithromycin and PPIs may require dose adjustment. Amoxicillin may require dose adjustment in severe renal impairment.
* **Hepatic Impairment:** Clarithromycin and PPIs may require dose adjustment.
## Contraindications
* Hypersensitivity to amoxicillin, clarithromycin, other macrolides, penicillin derivatives, or PPIs.
* History of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use.
* Concurrent use with cisapride, pimozide, terfenadine, or astemizole (due to risk of QTc prolongation and arrhythmias).
* Severe hepatic impairment with concomitant renal impairment for clarithromycin.
* Consult product monographs for a full list of contraindications.
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, abdominal pain, taste disturbance, headache.
* **Serious:** *Clostridium difficile*-associated diarrhea, allergic reactions (including anaphylaxis), hepatic dysfunction, Stevens-Johnson syndrome, toxic epidermal necrolysis, QTc prolongation.
* Long-term PPI use may be associated with an increased risk of fractures, *Clostridium difficile* infection, and vitamin B12 deficiency.
## Key Drug Interactions
* **Clarithromycin:** Potent CYP3A4 inhibitor. Increases concentrations of simvastatin, lovastatin, colchicine, carbamazepine, cyclosporine, tacrolimus, theophylline, warfarin, and certain calcium channel blockers, leading to increased risk of toxicity. Avoid concurrent use with certain statins and drugs that prolong the QTc interval.
* **PPIs:** Can affect the absorption of other drugs by altering gastric pH (e.g., ketoconazole, itraconazole, ritonavir, certain HIV protease inhibitors, clopidogrel). May decrease the effectiveness of clopidogrel.
* **Amoxicillin:** May decrease the effectiveness of oral contraceptives.
## Monitoring
* Monitor for signs of hypersensitivity reactions.
* Assess for diarrhea and dehydration.
* Monitor liver function tests, especially with prolonged use or in patients with hepatic impairment.
* Consider *H. pylori* eradication confirmation testing (e.g., urea breath test, stool antigen test) typically 4-6 weeks after completion of therapy.
## Clinical Pearls
* Administer antibiotics at the prescribed intervals to maintain adequate drug concentrations.
* Ensure the full course of therapy is completed, even if symptoms improve.
* Reinforce the importance of taking all components of the combination therapy as prescribed.
* Counsel patients on potential side effects and when to seek medical attention.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information, including the package insert and local guidelines, for complete and up-to-date drug information.
